Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationHematologic NeoplasmsGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationTransplantation ChimeraStem CellsBone Marrow TransplantationTreatment OutcomeGraft vs Leukemia EffectMyeloablative AgonistsVidarabineLeukemiaTissue DonorsBusulfanRecurrenceRemission InductionGraft vs Tumor EffectMultiple MyelomaGraft SurvivalHistocompatibility TestingLeukemia, Myeloid, AcuteRetrospective StudiesLymphocyte TransfusionCord Blood Stem Cell TransplantationImmunosuppressive AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMinor Histocompatibility AntigensCombined Modality TherapyHematopoietic Stem CellsMyelodysplastic SyndromesPrecursor Cell Lymphoblastic Leukemia-LymphomaSiblingsSurvival AnalysisCytomegalovirus InfectionsSalvage TherapySurvival RateDisease-Free SurvivalWhole-Body IrradiationLiver TransplantationLymphocyte DepletionAntilymphocyte SerumVirus ActivationNeoplasm, ResidualHistocompatibilityImmunocompromised HostMelphalanTime FactorsChimerismAntineoplastic Combined Chemotherapy ProtocolsHematologic DiseasesHepatic Veno-Occlusive DiseaseAntineoplastic AgentsT-LymphocytesMesenchymal Stem Cell TransplantationAcute DiseaseCyclophosphamideCytomegalovirusHematopoietic Stem Cell MobilizationPrognosisFollow-Up StudiesPrimary MyelofibrosisCell TransplantationAnemia, AplasticAntigens, CD34Kidney TransplantationLymphoproliferative DisordersLymphoma, Non-HodgkinHLA AntigensLymphomaBenzamidesLeukemia, MyeloidEmbryonic Stem CellsHodgkin DiseaseOpportunistic InfectionsLeukemia, Myeloid, Accelerated PhasePyrimidinesAspergillosisAntibodies, NeoplasmMycosesTransplantation ImmunologyFatal OutcomeRoseolovirus InfectionsImmunosuppressionCytarabineAdult Stem CellsPiperazinesInfectionFusion Proteins, bcr-ablGranulocyte Colony-Stimulating FactorFlow CytometryReceptors, Purinergic P2X5Leukemia, Lymphocytic, Chronic, B-CellNuclear FamilyNeoplasmsGraft RejectionProspective Studies